Nanocochleate-Driven Antidiabetic Drug Treatment: Advances in Synthetic and Herbal Compounds
International Journal of Drug Delivery Technology · 24.04.2026 · 16 (18s)
DOI: 10.25258/ijddt.16.18s.75 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 24.04.2026. Verfasst von Shubham K Sanjekar und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Diabetes mellitus (DM) is a long-term metabolic condition that impacts approximately one in every nine adults globally. Presently, oral antidiabetic medications like metformin and glibenclamide have limited absorption in the intestines, often necessitating higher doses that can cause systemic side effects. Meanwhile, peptide medications such as insulin require frequent injections due to their breakdown by enzymes in the gastrointestinal tract. To address these challenges, drug delivery systems based on nanotechnology have been developed as a promising solution. Among these, nanocochleates ; a new type of lipid-based nanocarrier with a distinctive cigar-shaped, multilayered roll-like structure formed through the interaction of anionic phospholipids and divalent cations (Ca²⁺)have shown significant potential for oral drug delivery. This review offers an in-depth examination of nanocochleate-based formulations for antidiabetic treatment, focusing on three primary drug types: the small-molecule biguanide metformin, the peptide hormone insulin, and herbal phytoconstituents like curcumin, quercetin, and andrographolide. The article explores preparation methods, such as trapping and direct calcium bridging techniques, and their effects on drug stability and bioavailability. Preclinical results indicate that insulin-loaded nanocochleates provide sustained glucose regulation, metformin-loaded systems show up to a fivefold increase in oral bioavailability, and phytochemical-loaded nanocochleates enhance therapeutic effectiveness and shelf life. Additionally, this review summarizes comparative studies to identify formulation trends and existing research gaps. Despite encouraging results, challenges like aggregation, scalability, and regulatory hurdles need to be overcome for successful clinical application. Overall, nanocochleates offer a promising and innovative platform for the oral delivery of antidiabetic agents, enhancing stability, bioavailability, and patient adherence, which could significantly impact diabetes management in the future
Zitieren
APA
Sanjekar, S. K., Pawar, S. S., & Mahore, J. G. (2026). Nanocochleate-Driven Antidiabetic Drug Treatment: Advances in Synthetic and Herbal Compounds. International Journal of Drug Delivery Technology, 16(18s). https://doi.org/10.25258/ijddt.16.18s.75
Vancouver
Sanjekar SK, Pawar SS, Mahore JG. Nanocochleate-Driven Antidiabetic Drug Treatment: Advances in Synthetic and Herbal Compounds. International Journal of Drug Delivery Technology. 2026;16(18s). doi:10.25258/ijddt.16.18s.75
BibTeX
@article{Sanjekar2026,
author = {Sanjekar, Shubham K and Pawar, Sayali S and Mahore, Jayashri G},
title = {Nanocochleate-Driven Antidiabetic Drug Treatment: Advances in Synthetic and Herbal Compounds},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {18s},
doi = {10.25258/ijddt.16.18s.75}
}
EUVIMED